

# Summary of MGuard™ Clinical Outcomes

## August 2010

Author/PI	No. of patients	Highlights	Publications/scientific meetings
Dariusz <b>Dudek</b> Institute of Cardiology, Krakow, Poland (MAGICAL Trial)	<b>60</b>	STEMI patients, multi-center 90% TIMI flow 3 73% Blush grade 3 0% MACCE at 30 days 1.7% MACCE at 6 months* *one ischemic stroke event	TCT 2009, SOLACI 2010
Alexandre <b>Abizaid</b> Institute Dante Pazzanese de Cardiology, São Paulo, Brazil (INSPIRE Trial)	<b>30</b>	SVG and native coronaries including ACS No EPD used 3.3% MACE at 30 days 17% TVR at 1 year 0% Death at 1 year	<a href="#">Cat. and Cardio. Int. Vol. 76 Issue 1, Pages 86 - 92; 2010</a>  <a href="#">J. Am. Coll. Cardiol. 2010;55:A180.E1680</a>
Eberhard <b>Grube</b> , Siegburg, Germany (First in Man Trial)	<b>41</b>	Stable angina in SVG and native lesion No EPD used 3% MACE at 30 days 19.5% TLR 6 months 22% MACE at 6 months	<a href="#">The Journal of Invasive Cardiology ; Vol. 20 Issue 10 ; 2008</a>
Eugenio <b>Martuscelli</b> , Rome, Italy	<b>22</b>	SVG patients No EPD used 91% TIMI 3 0% angiographic evidence of no-reflow	<a href="#">ESC 2009 abstract (ESC P4087)</a>
Federico <b>Piscione</b> , Naples, Italy.	<b>100</b>	STEMI patients (n= 84, excluding cardiogenic shock) 100% Device success Final cTFC = 17.2 90% MBG 3 90% Complete ST-segment resolution	<a href="#">Cat. and Cardio. Int. Vol. 75 Issue 5, pages 715-721 ; 2009</a>
Jain <b>Ajay</b> , Roshan <b>Weerackody</b> – London Chest Hospital, London, UK	<b>51</b>	STEMI patients (n= 49, excluding cardiogenic shock) 0% death or MI at 12 months 6% TVR at 12 months 96% ST Segment resolution (>50%) 100% TIMI 3 flow 100% Procedural success	<a href="#">Cat. and Cardio. Int. Vol 74, Issue 1, pages 88-93 ; 2009</a>  <a href="#">Eurointervention Vol. 6 Supp. H ; May 2010</a>
Hana <b>Vaknin-Assa</b> , Ran Kornowski Rabin Medical Center, Petach Tikva, Israel	<b>41</b>	41 patients (83% with SVG lesions) 100% Procedural success 98% Final TIMI 3 flow 7.3% MACE at 30 days 22% MACE at 6 months	<a href="#">Cat. and Cardio. Int. Vol. 74 Issue 7 ; 2009</a>  <a href="#">Israel cardiology society congress, 2010</a>
<b>Varshitzky</b> , Boguslavsky, Loncar, Danenberg, Admon, Nassar, Lotan, Hadasaah, Jerusalem, Israel	<b>38</b>	38 patients (45% STEMI, 32% SVG) 100% procedural success 89% final TIMI 3 flow Clinical follow-up at a mean of 5 ±2.3 months: 2.6% Death, 8% Restenosis, 2.6% TLR	<a href="#">Israel cardiology society congress, 2010</a>
<b>Abizaid, Danzi, Lotan</b> Interim analysis of a real world registry (iMOS Registry)	<b>211</b>	77% STEMI 87% visible thrombus 96% TIMI 3 flow 98% Procedural success 3.8% MACE at 30 days	SOLACI 2010

**Total Patients 594**